Delving into the Latest Updates on Acea Bio (Hangzhou) Co., Ltd. with Synapse

Overview

Tags

Immune System Diseases

Respiratory Diseases

Hemic and Lymphatic Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	1
Immune System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

EGFR T790M(Epidermal Growth Factor Receptor T790M)	1

评价马来酸艾维替尼胶囊对EGFR T790M突变阳性的晚期非小细胞肺癌患者的总体客观肿瘤缓解率（ORR）、缓解持续时间（DOR）、安全性、疾病无进展生存时间(PFS)、疾病控制率（DCR）、总生存期（OS）、肺癌症状和健康相关的生活质量（HRQoL），群体药代动力学研究

[Translation]

A population pharmacokinetic study to evaluate the overall objective tumor response rate (ORR), duration of response (DOR), safety, progression-free survival (PFS), disease control rate (DCR), overall survival (OS), lung cancer symptoms and health-related quality of life (HRQoL) of Avitinib Maleate Capsules in patients with advanced non-small cell lung cancer with EGFR T790M mutation.

Start Date18 May 2017

Sponsor / Collaborator

Hangzhou ACEA Pharmaceutical Research Co. Ltd.

[+1]

CTR20170108

/ Active, not recruitingPhase 1

马来酸艾维替尼胶囊治疗复发或难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤等非霍奇金淋巴瘤的I期临床试验

[Translation] Phase I clinical trial of Avitinib Maleate Capsules in the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and other non-Hodgkin's lymphomas

确定马来酸艾维替尼治疗复发或难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤、套细胞淋巴瘤、弥漫性大B-细胞淋巴瘤的进一步研究的推荐剂量

[Translation]

To determine the recommended dose of avitinib maleate for further studies in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, and diffuse large B-cell lymphoma

Start Date09 Mar 2017

Sponsor / Collaborator

Hangzhou ACEA Pharmaceutical Research Co. Ltd.

[+1]

CTR20160705

/ Active, not recruitingPhase 1

马来酸艾维替尼治疗EGFR T790M突变阳性的晚期NSCLC放射性研究后续服用马来酸艾维替尼胶囊安全性和初步疗效观察

[Translation] A radiological study of ivitatinib maleate in the treatment of EGFR T790M mutation-positive advanced NSCLC: safety and preliminary efficacy observation of subsequent administration of ivitatinib maleate capsules

评价男性EGFR T790M突变阳性的晚期NSCLC患者单剂量口服[14C]艾维替尼放射性研究后继续服用马来酸艾维替尼胶囊的安全性和初步疗效

[Translation]

To evaluate the safety and preliminary efficacy of avitinib maleate capsules in male patients with advanced NSCLC positive for EGFR T790M mutation after a single oral dose of [14C] avitinib radiostudy

Start Date18 Jan 2017

Sponsor / Collaborator

Hangzhou ACEA Pharmaceutical Research Co. Ltd.

[+1]

100 Clinical Results associated with Acea Bio (Hangzhou) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Acea Bio (Hangzhou) Co., Ltd.

Login to view more data

3

Literatures (Medical) associated with Acea Bio (Hangzhou) Co., Ltd.

30 Sep 2021·Zhongguo yi liao qi xie za zhi = Chinese journal of medical instrumentation

[Brief Introduction about New Regulation of EU on IVDR].

Article

Author: Chen, Zhihui

There are five-year transitional period for manufacturers after the issue of regulation(EU) 2017/746 on in vitro diagnostic medical devices(IVDR) in May, 2017. The article introduces the background, major change, the impact of new regulation and the coping strategies of enterprises, the main preparation work should be taken etc, to provide reference or help for the domestic manufacturers when they prepare the CE marking according to IVDR.

30 Jul 2018·Zhongguo yi liao qi xie za zhi = Chinese journal of medical instrumentation

[Practice of Medical Device Clinical Evaluation].

Article

Author: Lyu, Hongguang

For medical device clinical evaluation activities, reference to international and domestic medical device regulations and guidance documents, this paper briefly introduces the implementation steps of clinical evaluation of medical devices, and focus on the evaluation report should be included in the content, provides reference for relevant personnel of medical devices registration and certification on medical device clinical evaluation practice.

01 Aug 2015·Antimicrobial Agents and ChemotherapyQ2 · MEDICINE

Artemether Exhibits Amoebicidal Activity against Acanthamoeba castellanii through Inhibition of the Serine Biosynthesis Pathway

Q2 · MEDICINE

Article

Author: Gao, Hongjian ; Deng, Yihong ; Li, Xueping ; Tang, Wei ; Man, Suqin ; Ran, Wei ; Tachibana, Hiroshi ; Cheng, Xunjia

ABSTRACTAcanthamoeba sp. parasites are the causative agents of Acanthamoeba keratitis, fatal granulomatous amoebic encephalitis, and cutaneous infections. However, there are currently no effective drugs for these organisms. Here, we evaluated the activity of the antimalarial agent artemether against Acanthamoeba castellanii trophozoites and identified potential targets of this agent through a proteomic approach. Artemether exhibited in vitro amoebicidal activity in a time- and dose-dependent manner and induced ultrastructural modification and cell apoptosis. The iTRAQ quantitative proteomic analysis identified 707 proteins that were differentially expressed after artemether treatment. We focused on phosphoglycerate dehydrogenase and phosphoserine aminotransferase in the serine biosynthesis pathway because of their importance to the growth and proliferation of protozoan and cancer cells. The expression of these proteins in Acanthamoeba was validated using quantitative real-time PCR and Western blotting after artemether treatment. The changes in the expression levels of phosphoserine aminotransferase were consistent with those of phosphoglycerate dehydrogenase. Therefore, the downregulation of phosphoserine aminotransferase may be due to the downregulation of phosphoglycerate dehydrogenase. Furthermore, exogenous serine might antagonize the activity of artemether against Acanthamoeba trophozoites. These results indicate that the serine biosynthesis pathway is important to amoeba survival and that targeting these enzymes would improve the treatment of Acanthamoeba infections. Artemether may be used as a phosphoglycerate dehydrogenase inhibitor to control or block Acanthamoeba infections.

100 Deals associated with Acea Bio (Hangzhou) Co., Ltd.

Login to view more data

100 Translational Medicine associated with Acea Bio (Hangzhou) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 27 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

3

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Avitinib Maleate ( EGFR T790M )	Non-Small Cell Lung Cancer More	Phase 3
A-348	Neoplasms More	Pending
Fluorapacin ( Tubulin )	Advanced cancer More	Pending
A-0404	Neoplasms More	Pending